HOOKIPA Pharma (HOOK) Study Update Presentation summary

Arenavirus immunotherapy platform overview

• Arenavirus-based vectors engineered to activate robust, polyfunctional T cell responses for tumor elimination, with demonstrated safety and off-the-shelf availability.

• Platform enables modification with multiple antigens, targeting diverse cancers and infectious diseases.

• Natural tropism to dendritic cells ensures efficient immune activation and tumor targeting.

HB-200: HPV16+ head and neck cancer program

• Alternating two-vector therapy (LCMV and PICV) optimized for strong, durable CD8+ T cell responses against HPV16 antigens.

• Phase 2 data show 44% disease control rate and 33% tumor shrinkage as monotherapy; ORR doubled versus standard of care in combination with pembrolizumab.

• Combination with pembrolizumab achieved 53% ORR and 18% complete response in PD-L1 CPS ≥20 patients, with durable responses.

• Pivotal randomized trial of HB-200 plus checkpoint inhibitor versus checkpoint inhibitor alone to start in 2024.

• Therapy induces robust, sustained, and polyfunctional HPV16-specific CD8+ T cell responses in most patients.

HB-700: KRAS-mutant cancer program

• HB-700 targets five prevalent KRAS mutations (G12D, G12V, G12C, G12R, G13D) in pancreatic, colorectal, and lung cancers.

• Preclinical studies show strong, mutation-specific T cell activation and cytotoxicity with minimal off-target effects.

• Alternating two-vector design (HB-703/LCMV and HB-704/PICV) maximizes immunogenicity and T cell induction.

• IND cleared by FDA in April 2024; Phase 1 trial ready to initiate with drug product available.

• Platform supports combination with checkpoint inhibitors, KRAS inhibitors, degraders, and T cell therapies for synergistic effects.